Thuy Tran

About me
Publications
Grants
CV
Public outreach and news

About me

I obtained a PhD in 2009 from Uppsala University and received my Docent/readership in 2016 from Lund University in experimental oncology with a focus on molecular imaging and radiochemistry.

I have more than 14 years’ experience in both preclinical and clinical research in the fields of nuclear medicine, radionuclide production, molecular imaging, and antibody-based theranostics. Currently, I lead the TRANslational Theranostics group, which is dedicated to advancing theranostics - an elegant approach that seamlessly integrates diagnostics and therapy in one solution, revolutionizing precision medicine in cancer management.

Education:
2016 Docent in experimental oncology, Lund University
2009 Ph.D. Degree, specialized in Molecular imaging and radiometal chemistry, Uppsala University
2008 Master Degree in Medical radionuclide techniques, Uppsala University
2005 Master of Science in Pharmacy, Uppsala University

Research

My research group focuses on the development of theranostics, i.e. radiopharmaceuticals for precision diagnostics, therapy and monitoring of diseases, with the emphasis in oncological diseases. We conduct studies to identify new targets and screen for new drugs for cancer treatments. In parallel, we perform novel developments of non-conventional radiometals using solid target on cyclotron, novel radiotracer developments, and biological evaluation studies in vitro and in vivo to clinical translation.

We are a multidisciplinary team consisting of pharmacists, radiochemists, medicine doctoral students, medical physicists and biologists. We collaborate closely and broadly with other research groups for generating drug screening, target identification, and clinicians, oncologists, and radiologists for clinical translation.

Read more about my research team and our projects here! [1]
[1] https://ki.se/en/onkpat/research-team-thuy-tran

Articles

Article: EJNMMI RADIOPHARMACY AND CHEMISTRY. 2023;8(1):42

Microfluidic-based production of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer.

Mallapura H; Ovdiichuk O; Jussing E; Thuy TA; Piatkowski C; Tanguy L; Collet-Defossez C; Långström B; Halldin C; Nag S
Article: EJNMMI RADIOPHARMACY AND CHEMISTRY. 2023;8(1):41

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer.

Jussing E; Ferrat M; Moein MM; Alfredéen H; Tegnebratt T; Bratteby K; Samén E; Feldwisch J; Altena R; Axelsson R; Tran TA
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108455

O-59 Preclinical evaluation of [89Zr]Zr-DFO*-sacituzumab, a PET tracer for imaging of whole body TROP-2 expression as a potential selection tool for treatment with TROP-2 antibody drug conjugates (ADC)

Bratteby K; Smertinaite L; Omer S; Lu L; Milton S; Jussing E; Siikanen J; Samen E; Axelsson R; Foukakis T; Altena R; Tran T
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108801

P-343 Targeting brain tumours with radiolabelled chlorotoxin, a scorpion venom peptide

Zafar I; Li K; Zammit J; Palm KP; Davydova M; Varshney M; Lu L; Tran T; Bergstrom T; Swartling FJ; Lewis J; Holmin S; Goos J
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108673

P-208 In vivo evaluation and optimization of [89Zr]Zr-DFO-NCS and [89Zr] Zr-(oxinate)4 for cell tracking

Friberger I; Tran T; Lu L; Milton S; Samen E; Goos J; Carlsten M; Holmin S
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108721

P-258 First time evaluation of 45Ti for radiolabeling of NOTA and DOTA chelators

Milton S; Jussing E; Bratteby K; Ferrat M; Samen E; Tran T; Siikanen J
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108800

P-342 Cancer theranostics using radiolabelled PARP inhibitors

Ferrat M; Mercier G; Milton S; Mohammad M; Samen E; Tran T
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108529

P-057 Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer

Jussing E; Alfredéen H; Moein MM; Tegnebratt T; Bratteby K; Samen E; Altena R; Axelsson R; Tran T
Journal article: ANNALS OF ONCOLOGY. 2023;34:s384

Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer

af Buren S; Axelsson R; Jussing E; Karlsson M; Blomgren A; Brun N; Frejd FY; Tran TA; Altena R
Article: EJNMMI RESEARCH. 2023;13(1):73

Comparative in vivo biodistribution of cells labelled with [89Zr]Zr-(oxinate)4 or [89Zr]Zr-DFO-NCS using PET.

Friberger I; Nilsson JN; Lu L; Siikanen J; Ardenfors O; Milton S; Samén E; Goos JACM; Carlsten M; Holmin S; Tran TA
Article: JOURNAL OF NUCLEAR MEDICINE. 2023;64(8):1232-1237

Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial.

Rasinski P; Af Burén S; Holstensson M; Nilsson T; Loizou L; Tran TA; Sparrelid E; Löhr JM; Axelsson R
Article: CELL TRANSPLANTATION. 2023;32:9636897231212780

Phenotyping of Macrophages After Radiolabeling and Safety of Intra-arterial Transplantation Assessed by SPECT/CT and MRI.

Friberger I; Gontu V; Harris RA; Tran TA; Lundberg J; Holmin S
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:s197-s198

P-271 Preparation and cGMP-compliant production of the bombesin analogue [68Ga]Ga-NOTA-RM26 for first-in-human clinical study of gastrin-releasing peptide receptor expression in prostate cancer

Jussing E; Moein MM; Tegnebratt T; Semetaite V; Liepins E; Tzortzakakis A; Axelsson R; Orlova A; Tran T
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:s122-s123

P-133 Automated radiolabeling of [68Ga]Ga-DOTATOC using the iMiDEV™ automated microfluidic radiosynthesizer

Chandrashekara HK; Tran T; Jussing E; Tanguy L; Långström B; Le Meunier L; Halldin C; Nag S
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:s132-s133

P-153 High yield GMP production of [18F]FE-PE2I, a radiotracer for in vivo PET imaging the dopamine transporter

Moein MM; Dahl K; Meijer E; Ferrat M; Tegnebratt T; Saliba P; Norman F; Samen E; Steiger C; Savitcheva I; Tran T
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:s216-s217

P-307 Comparative in vivo biodistribution and dosimetry in non-human primate of the fibroblast activation protein radiotracers [68Ga]Ga-FAPI-04, [68Ga]Ga-FAPI-46 and [18F]FAPI-74

Tran T; Bolin M; Dahl K; Johnstrom P; Mitran B; Siikanen J; Schou M
Article: PHARMACEUTICALS. 2021;14(12):1251

Humanization, Radiolabeling and Biodistribution Studies of an IgG1-Type Antibody Targeting Uncomplexed PSA for Theranostic Applications.

Strand J; Sjöström K; Lamminmaki UJ; Vilhelmsson Timmermand O; Strand S-E; Tran TA
Article: MOLECULAR IMAGING AND BIOLOGY. 2021;23(6):952-962

Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications.

Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samén E; Carlsten M; Holmin S; Tran TA
Article: APPLIED RADIATION AND ISOTOPES. 2021;176:109825

Cyclotron-produced 68Ga from enriched 68Zn foils.

Siikanen J; Jussing E; Milton S; Steiger C; Ulin J; Jonsson C; Samén E; Tran TA
Article: BIOMOLECULES. 2021;11(8):1118

Clinically Applicable Cyclotron-Produced Gallium-68 Gives High-Yield Radiolabeling of DOTA-Based Tracers.

Jussing E; Milton S; Samén E; Moein MM; Bylund L; Axelsson R; Siikanen J; Tran TA
Article: CANCERS. 2021;13(14):3469

A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.

Vilhelmsson Timmermand O; Örbom A; Altai M; Zedan W; Holmqvist B; Safi M; Tran TA; Strand S-E; Strand J
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2021;64(8):346-352

Fully automated production of the fibroblast activation protein radiotracer [18 F]FAPI-74.

Dahl K; Jussing E; Bylund L; Moein MM; Samén E; Tran T
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2021;41(3):617-629

The cellular basis of increased PET hypoxia tracer uptake in focal cerebral ischemia with comparison between [18F]FMISO and [64Cu]CuATSM.

Little PV; Arnberg F; Jussing E; Lu L; Ingemann Jensen A; Mitsios N; Mulder J; Tran TA; Holmin S
Article: INTERNATIONAL JOURNAL OF NANOMEDICINE. 2020;15:6137-6152

Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe.

Ahmed M; Tegnebratt T; Tran TA; Lu L; Damberg P; Gisterå A; Tarnawski L; Bone D; Hedin U; Eriksson P; Holmin S; Gustafsson B; Caidahl K
Article: ANTIOXIDANTS & REDOX SIGNALING. 2019;30(14):1746-1759

Protection of Kidney Function with Human Antioxidation Protein α1-Microglobulin in a Mouse 177Lu-DOTATATE Radiation Therapy Model.

Kristiansson A; Ahlstedt J; Holmqvist B; Brinte A; Tran TA; Forssell-Aronsson E; Strand S-E; Gram M; Åkerström B
Article: THERANOSTICS. 2019;9(8):2129-2142

Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics.

Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand S-E
Journal article: FREE RADICAL BIOLOGY AND MEDICINE. 2018;120:s99-s100

Protection of kidney function with human antioxidation protein α1-microglobulin (A1M) in a mouse 177Lu-DOTATATE radiation therapy model

Kristiansson A; Ahlstedt J; Holmqvist B; Brinte A; Tran TA; Forssell-Aronsson E; Strand S-E; Gram M; Akerstrom B
Article: PHYSICS IN MEDICINE AND BIOLOGY. 2017;63(1):015026

135La as an Auger-electron emitter for targeted internal radiotherapy.

Fonslet J; Lee BQ; Tran TA; Siragusa M; Jensen M; Kibédi T; Stuchbery AE; Severin GW
Article: SCIENTIFIC REPORTS. 2017;7(1):4824

Combined Magnetomotive ultrasound, PET/CT, and MR imaging of 68Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo.

Evertsson M; Kjellman P; Cinthio M; Andersson R; Tran TA; In't Zandt R; Grafström G; Toftevall H; Fredriksson S; Ingvar C; Strand S-E; Jansson T
Article: EJNMMI RESEARCH. 2016;6(1):27

Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.

Vilhelmsson Timmermand O; Larsson E; Ulmert D; Tran TA; Strand S
Article: NUCLEAR MEDICINE AND BIOLOGY. 2015;42(4):375-380

Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

Vilhelmsson-Timmermand O; Santos E; Thorek DLJ; Evans-Axelsson S; Bjartell A; Lilja H; Larson SM; Strand S-E; Tran TA; Ulmert D
Article: JOURNAL OF NUCLEAR MEDICINE. 2015;56(3):444-449

Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.

Timmermand OV; Tran TA; Strand S-E; Axelsson J
Article: AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2015;5(4):333-347

Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys.

Ahlstedt J; Tran TA; Strand F; Holmqvist B; Strand S-E; Gram M; Åkerström B
Article: EJNMMI RESEARCH. 2014;4(1):51

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.

Timmermand OV; Ulmert D; Evans-Axelsson S; Pettersson K; Bjartell A; Lilja H; Strand S-E; Tran TA
Article: APPLIED RADIATION AND ISOTOPES. 2014;94:294-301

A solid target system with remote handling of irradiated targets for PET cyclotrons.

Siikanen J; Tran TA; Olsson TG; Strand S-E; Sandell A
Article: AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;4(4):311-323

Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer.

Evans-Axelsson S; Vilhelmsson Timmermand O; Welinder C; Borrebaeck CA; Strand S-E; Tran TA; Jansson B; Bjartell A
Article: AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;4(1):60-69

(68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes.

Madru R; Tran TA; Axelsson J; Ingvar C; Bibic A; Ståhlberg F; Knutsson L; Strand S-E
Article: JOURNAL OF NUCLEAR MEDICINE. 2012;53(6):953-960

Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.

Tolmachev V; Tran TA; Rosik D; Sjöberg A; Abrahmsén L; Orlova A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2011;39(2):353-359

Effects of affinity on binding of HER2-targeting Affibody molecules: model experiments in breast cancer spheroids.

Qvarnström OF; Simonsson M; Carlsson J; Tran TA
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2010;37(2):260-269

(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Orlova A; Tran TA; Ekblad T; Karlström AE; Tolmachev V
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36(11):1864-1873

Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.

Tran TA; Rosik D; Abrahmsén L; Sandström M; Sjöberg A; Wållberg H; Ahlgren S; Orlova A; Tolmachev V
Article: JOURNAL OF NUCLEAR MEDICINE. 2009;50(5):781-789

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
Article: BIOCONJUGATE CHEMISTRY. 2008;19(12):2568-2576

Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.

Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2008;35(12):2245-2255

Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.

Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V
Article: BIOCONJUGATE CHEMISTRY. 2007;18(6):1956-1964

(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.

Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2007;34(11):1843-1853

99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.

Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2007;20(3):397-404

Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.

Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2007;34(5):722-733

Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

Engfeldt T; Orlova A; Tran T; Bruskin A; Widström C; Karlström AE; Tolmachev V
Article: CANCER RESEARCH. 2007;67(5):2178-2186

Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.

Orlova A; Tolmachev V; Pehrson R; Lindborg M; Tran T; Sandström M; Nilsson FY; Wennborg A; Abrahmsén L; Feldwisch J
Article: BIOCONJUGATE CHEMISTRY. 2007;18(2):549-558

In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.

Tran T; Engfeldt T; Orlova A; Widström C; Bruskin A; Tolmachev V; Karlström AE
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2007;19(3):485-493

Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.

Tran T; Orlova A; Sivaev I; Sandström M; Tolmachev V
Show more

All other publications

Letter: JOURNAL OF NUCLEAR MEDICINE. 2023;64(11):1841

HER2-Low Breast Cancer Can Be Visualized by HER2 PET.

Altena R; Af Burén S; Tran T; Axelsson R
Preprint: 2023;Research Square

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer

Jussing E; Ferrat M; Moein MM; Alfredéen H; Tegnebratt T; Bratteby K; Samén E; Feldwisch J; Altena R; Axelsson R; Tran TA
Review: EJNMMI RESEARCH. 2023;13(1):43

Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications.

Altena R; Tzortzakakis A; Af Burén S; Tran TA; Frejd FY; Bergh J; Axelsson R
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2023;50(SUPPL 1):S493

A dose optimization study using Visual Grading Regression in [68Ga]-FAPI-46 PET imaging of patients with pancreatic lesions

Nilsson T; Rasinski P; af Buren S; Smedby O; Blomgren A; Lohr M; Sparrelid E; Tran T; Axelsson R; Holstensson M
Editorial comment: CLINICAL NUCLEAR MEDICINE. 2022;47(7):644-645

A 68Ga-FAPI-46 PET/CT Imaging Pitfall in Assessing Residual Gastric Cancer Early After Chemotherapy.

Af Burén S; Tran TA; Klevebro F; Holstensson M; Axelsson R
Corrigendum: MOLECULAR IMAGING AND BIOLOGY. 2022;24(3):510

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications.

Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samén E; Carlsten M; Holmin S; Tran TA
Book chapter: 2022;p. 1-11

Principles behind Radiopharmacy

Tran TA; Samén E
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:S197-S198

Preparation and cGMP-compliant production of the bombesin analogue [⁶⁸Ga]Ga-NOTA-RM26 for first-in-human clinical study of gastrin-releasing peptide receptor expression in prostate cancer

Jussing E; Moein MM; Tegnebratt T; Semetaite V; Liepins E; Tzortzakakis A; Axelsson R; Orlova A; Thuy T
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:S216-S217

Comparative in vivo biodistribution and dosimetry in non-human primate of the fibroblast activation protein radiotracers [⁶⁸Ga]Ga-FAPI-04, [⁶⁸Ga]Ga-FAPI-46 and [¹⁸F]FAPI-74

Thuy T; Bolin M; Dahl K; Johnstrom P; Mitran B; Siikanen J; Schou M
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:S132-S133

High yield GMP production of [¹⁸F]FE-PE2I, a radiotracer for in vivo PET imaging the dopamine transporter

Moein MM; Dahl K; Meijer E; Ferrat M; Tegnebratt T; Saliba P; Norman F; Samen E; Steiger C; Savitcheva I; Tran T
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:S122-S123

Automated radiolabeling of [⁶⁸Ga]Ga-DOTATOC using the iMiDEV™ automated microfluidic radiosynthesizer

Chandrashekara HK; Thuy T; Jussing E; Tanguy L; Langstrom B; Le Meunier L; Halldin C; Nag S
Review: JOURNAL OF CHROMATOGRAPHY A. 2020;1632:461611

Application of chiral chromatography in radiopharmaceutical fields: A review.

Moein MM; Tran TA
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2019;46(SUPPL 1):S38-S39

Cyclotron Production of ⁶⁸Ga Using Enriched ⁶⁸Zn Foils

Siikanen J; Jussing E; Milton S; Steiger C; Ulin J; Tran T; Samen E
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2019;62:S551-S552

Optimization of ⁸⁹Zr-based radiotracers for long-term in vivo cell tracking with PET imaging

Jonsson I; Jussing E; Zhang X-M; Lu L; Samen E; Harris R; Holmin S; Thuy T
Conference publication: EUROPEAN HEART JOURNAL. 2019;40:674

Zirconium-89 labelled probe for molecular imaging of inflammation in experimental atherosclerosis

Ahmed M; Tegnebratt T; Tran T; Damberg P; Bone D; Lu L; Gistera A; Tarnawski L; Hedin U; Eriksson P; Holmin S; Gustafsson B; Caidahl K
Conference publication: 2016;:1-4

An Attenuation Method for Reducing Count Rate Losses in Preclinical PET During Intratherapeutic Imaging

Mellhammar E; Dahlbom M; Evans-Axelsson S; Axelsson J; Tran T; Strand S-E
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2015;16(12):30309-30320

Human Anti-Oxidation Protein A1M--A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy.

Ahlstedt J; Tran TA; Strand S-E; Gram M; Åkerström B
Conference publication: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2015;36:S115

Targeting human kallikrein 2 with 11B6 antibodies for radionuclide imaging and the treatment of prostate cancer

Tran TA; Timmermand OV; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2015;56(3)

Radioimmunoimaging and Radioimmunotherapy of Prostate Cancer. Preclinical evaluation of kallikrein related peptidase 2 targeting

Timmermand OV; Thuy T; Axelsson J; Elgqvist J; Ulmert D; Strand S-E
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2015;58:S24

¹³⁵La for Auger-based therapy: preparation, imaging and emissions

Fonslet J; Tran TA; Lee BQ; Siikanen J; Larsson E; Kibedi T; Stuchbery AE; Elema DR; Severin GW
Conference publication: 2014;:1-3

Effects of High Photon Fluence Rate from Therapeutic Radionuclides on Preclinical and Clinical PET Systems

Dahlbom M; Mellhammar E; Axelsson J; Tran T; Strand S-E
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;41:S412

Cerenkov Luminescence Imaging for Intratherapy Activity Monitoring in Pre-clinical Radionuclide Therapy

Axelsson J; Vilhelmsson-Timmermand O; Tran TA; Strand S
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;41:S280

Therapeutic Efficacy of 177Lu-labeled h11B6 in Prostate Cancer Xenografts

Timmermand OV; Elggvist J; Akesson A; Strand S; Tran TA
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55

In vivo evaluation of the radiolabeled ICAM-1 monoclonal antibody R6.5 in a prostate cancer mouse model

Axelsson SE; Trbom A; Jansson B; Timmermand OV; Tran T; Bjartell A; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55

Radiation sensitivity of prostate cancer cell lines for 177Lu, 111In, or photon irradiation

Elgqvist J; Claesson K; Larsson E; Oredsson S; Thuy T; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55

Combining optical Cherenkov luminescence imaging and SPECT for intratherapy dosimetry in preclinical radionuclide therapy

Axelsson J; Timmermand OV; Mellhammar E; Thuy T; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55

SPECT/CT imaging of the human kallikrein-2 (hK2) expression in prostate cancer using the humanized monoclonal antibody h11B6

Tran T; Elgqvist J; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55

In vivo evaluation of 177Lu-labeled h11B6, a humanized antibody for hK2 targeting in prostate cancer

Timmermand OV; Larsson E; Strand S-E; Thuy T
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2013;54

68Ga-labeled superparamagnetic nanoparticles for multiple PET/MR/Cherenkov luminescence imaging of sentinel nodes

Madru R; Axelsson J; Tran T; Bibic A; Ingvar C; Stahlberg F; Knutsson L; Strand S-E
Conference publication: AIP CONFERENCE PROCEEDINGS. 2012;1509(1):206-210

A peristaltic pump driven 89Zr separation module

Siikanen J; Peterson M; Tran TA; Roos P; Ohlsson T; Sandell A
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2012;53

Targeting the human kallikrein-2 (hK2) expression in prostate cancer using 111In-labelled monoclonal antibody 11B6

Thuy T; Timmermand OV; Axelsson SE; Pettersson K; Bjartell A; Lilja H; Ulmert D; Strand S-E
Editorial comment: ZDRAVNIŠKI VESTNIK. 2011;80(12):969-970

Imaging of Brain Prion Protein Amyloid in Patients with Gertstmann-Straussler-Scheinker Disease

Tran TA; Kirik D
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2011;52

Labeling proteins with ⁸⁹Zr separated from large yttrium bulks

Siikanen J; Ohlsson T; Sandell A; Strand S-E; Thuy T
Preprint: medRxiv

Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial

Altena R; Tran TA; Kjällquist U; Karlsson M; Siikanen J; Jussing E; Tzortzakakis A; Jonmarker O; Axelsson R; Bergh J
Show more

Grants

Molekylära och bildgivande tekniker för kardiovaskulär riskbedömning

Swedish Heart-Lung Foundation

1 January 2021 - 31 December 2021
Cell therapy in oncology using Interventional nuclear medicine

Swedish Research Council

1 January 2018 - 31 December 2020

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026
Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026
Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

About me

Research

Articles

All other publications

Grants

Employments

News from KI

Events from KI